Detecting heart rejection without a biopsy in children
Part of Heart & circulation clinical trials.
This trial tests if a special MRI can detect early signs of heart rejection in children and young adults who have had a heart transplant. If successful, it might reduce the need for invasive biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart transplant when you were 18 years old or younger.
- You are scheduled for a routine biopsy to check for rejection.
- You are at least 3 months past your heart transplant surgery.
- You can safely have an MRI with contrast dye (no allergies or kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a heart MRI can detect early signs of organ rejection after a heart transplant. If successful, it could reduce the need for frequent biopsies.
This trial uses precise, personalized approaches to manage heart transplant recipients. It involves taking a small heart muscle sample (a biopsy) to monitor for rejection or routine checks.
This study uses advanced heart imaging and blood tests to detect a type of rejection that can happen after a heart transplant. It may help doctors diagnose antibody-mediated rejection earlier and more accurately.
This study tests a new way to monitor heart transplant patients for rejection using blood tests and other non-invasive tools, which might reduce the need for invasive biopsies. If you've had a recent heart transplant and are stable, this study could help improve post-transplant care.
This study renews research using heart MRI scans to learn more about heart transplant patients and compare them with healthy control scans. It may help researchers understand heart function after transplant and improve future imaging care.
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Hear when a new Pediatric Heart Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.